You are here: Home » 2023 » Archives for June 2023

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Futu Holdings Limited Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – FUTU

NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminder purchasers of the securities of Futu Holdings Limited (NASDAQ: FUTU) between April 27, 2020 and May 16, 2023, both dates inclusive (the "Class Period"), of the important August 11, 2023 lead plaintiff deadline, in the securities class action commenced by the Firm.

SO WHAT: If you purchased Futu securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Futu class action, go to https://rosenlegal.com/submit–form/?case_id=16261 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 11, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose, among other things, that: (1) Futu's business was, quite simply, illegal as it related to operations in China as a result of its failure to obtain the proper licenses; (2) it did not fully disclose to investors that it was engaging in unlawful activity and instead falsely characterized the applicable Chinese laws as ambiguous; (3) the foregoing subjected the Company to a heightened risk of regulatory enforcement; and (4) as a result, defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Futu class action, go to https://rosenlegal.com/submit–form/?case_id=16261 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm's attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8867116)

AROW INVESTOR NEWS: ROSEN, A LEADING LAW FIRM, Encourages Arrow Financial Corporation Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AROW

NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Arrow Financial Corporation (NASDAQ: AROW) between March 12, 2022 and May 12, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 22, 2023

SO WHAT: If you purchased Arrow securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Arrow class action, go to https://rosenlegal.com/submit–form/?case_id=17331 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 22, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements regarding the Company's business, operations, and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose to investors that: (1) Arrow maintained defective disclosure controls and procedures and internal controls over financial reporting; (2) the foregoing increased the risk that the company could not timely file one or more of its periodic financial reports with the SEC as required by the NASDAQ's listing requirements; (3) accordingly, Arrow was at an increased risk of being delisted from the NASDAQ; (4) following the disclosure of deficiencies in the Company's disclosure controls and procedures and internal controls over financial reporting, Arrow downplayed the severity of these issued and the associated risks; and (5) as a result, the Company's public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Arrow class action, go to https://rosenlegal.com/submit–form/?case_id=17331 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8867110)

Curia wins 2023 Frost & Sullivan Customer Value Leadership Award

ALBANY, N.Y., June 29, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced it has been awarded a Best Practices Customer Value Leadership Award in the CRDMO industry by Frost & Sullivan.

"We are very honored to be recognized with this award, which underlines the hard work and dedication of all of our employees to delivering quality and reliability when serving our customers," said Philip Macnabb, CEO, Curia. "We remain steadfast in our noble purpose of improving patients' lives, a mission that begins with our commitment to creating value for our customers."

Frost & Sullivan noted in its report that the company's rebrand from AMRI to Curia in 2021 put a focus on science at the center of its brand identity, highlighting a pledge to help customers advance "from curiosity to cure." Curia has evolved over time to offer a comprehensive range of services from drug discovery through development to manufacture of both drug substance and drug product for pharmaceutical and biologics companies. The award recognizes how Curia seeks out innovative solutions by using the latest technologies to efficiently move products from discovery to development to commercial scale to accelerate speed to market for its customers. This continuous commitment to serve unspoken market needs and deliver end–to–end solutions for customers has positioned it as an industry leader.

"Curia has built its reputation by offering a best–in–class customer ownership and service experience. The company surveys clients to gauge their overall satisfaction and ensure that it is upholding the highest standards," said Unmesh Lal, director, Healthcare & Life Sciences, Frost & Sullivan.

Each year, Frost & Sullivan employs a rigorous evaluation, measuring business and customer impact, to identify companies that consistently innovate to meet their customers' needs while navigating new challenges and opportunities. The winner is recognized for providing a superior customer experience for overall price, performance and quality.

About Curia
Curia, formerly AMRI, is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia's nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

About Frost & Sullivan
Frost & Sullivan is the Growth Pipeline Company. We power our clients to a future shaped by growth. Our Growth Pipeline as a Service provides the CEO and the CEO's growth team with a continuous and rigorous platform of growth opportunities, ensuring long–term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at http://www.frost.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com


GLOBENEWSWIRE (Distribution ID 8865503)

Curia recebe Prêmio de Liderança de Valor do Cliente 2023 Frost & Sullivan

ALBANY, N.Y., June 29, 2023 (GLOBE NEWSWIRE) — A Curia, uma organizao lder em contratos de pesquisa, desenvolvimento e fabricao, anunciou hoje que recebeu o Prmio de Melhor Prtica de Liderana de Valor do Cliente na indstria de CRDMO da Frost & Sullivan.

"Estamos muito honrados em receber este prmio que destaca o trabalho rduo e a dedicao de todos os nossos funcionrios em oferecer qualidade e confiabilidade ao servir nossos clientes", disse Philip Macnabb, CEO da Curia. "Continuamos firmes no nosso nobre propsito de melhorar a vida dos pacientes, uma misso que tem incio com o nosso compromisso de criar valor para nossos clientes."

No seu relatrio a Frost & Sullivan observou que a mudana da marca da empresa de AMRI para Curia em 2021 colocou o foco da cincia no centro da identidade da sua marca, destacando uma promessa de ajudar os clientes a avanar "da curiosidade para a cura". A Curia evoluiu ao longo do tempo para oferecer uma gama abrangente de servios, desde a descoberta de medicamentos at o desenvolvimento e fabricao de medicamentos e produtos farmacuticos para empresas farmacuticas e biolgicas. O prmio um reconhecimento de como a Curia procura solues inovativas por meio de tecnologias mais avanadas para avanar eficientemente os produtos da fase da descoberta para a fase do desenvolvimento em escala comercial, e acelerar a velocidade do lanamento no mercado para seus clientes. Esse compromisso contnuo de atender s necessidades tcitas do mercado e fornecer solues completas para os clientes a posicionou como lder do setor.

"A Curia desenvolveu sua reputao com a oferta de produtos e experincia de servios ao cliente de primeira classe. A empresa pesquisa os clientes para avaliar sua satisfao geral e garantir os mais altos padres de qualidade", disse Unmesh Lal, diretor de Sade e Cincias da Vida da Frost & Sullivan.

Todos os anos, a Frost & Sullivan faz uma avaliao rigorosa, medindo o impacto nos negcios e nos clientes, para identificar empresas que estejam inovando com consistncia para atender s necessidades dos seus clientes e navegar por novos desafios e oportunidades. O vencedor foi premiado por fornecer uma experincia superior ao cliente em termos de preos, desempenho e qualidade em geral.

Sobre a Curia
A Curia, ex–AMRI, uma organizao lder em contratos de pesquisa, desenvolvimento e fabricao que fornece produtos e servios de P&D por meio da fabricao comercial para clientes farmacuticos e biofarmacuticos. Os quase 4.000 funcionrios da Curia em 29 locais nos EUA, Europa e sia ajudam seus clientes a avanar da curiosidade para a cura. Saiba mais em CuriaGlobal.com.

Sobre a Frost & Sullivan
A Frost & Sullivan a Growth Pipeline Company. Capacitamos nossos clientes para um futuro moldado pelo crescimento. Nosso Growth Pipeline as a Service fornece aos CEOs e equipes de crescimento dos CEOs uma plataforma contnua e rigorosa de oportunidades de crescimento, garantindo o sucesso a longo prazo. Para alcanar resultados positivos, nossa equipe utiliza nossos mais de 60 anos de experincia para treinar organizaes de todos os tipos e tamanhos em 6 continentes com nossas melhores prticas comprovadas. Para impulsionar o seu Growth Pipeline futuro, visite a Frost & Sullivan em http://www.frost.com.

Contato da Curia:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com


GLOBENEWSWIRE (Distribution ID 8866428)

Curia wird 2023 Frost & Sullivan Customer Value Leadership Award verliehen

ALBANY, N.Y., June 29, 2023 (GLOBE NEWSWIRE) — Curia, ein fhrendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, gab heute bekannt, dass das Unternehmen von Frost & Sullivan mit dem Best Practices Customer Value Leadership Award in der CRDMO–Branche ausgezeichnet wurde.

"Wir fhlen uns durch diese Auszeichnung sehr geehrt, denn sie unterstreicht die harte Arbeit und das Engagement unserer Mitarbeiterinnen und Mitarbeiter, die im Dienste unserer Kunden Qualitt und Zuverlssigkeit bieten", sagte Philip Macnabb, CEO von Curia. "Wir bleiben unserem edlen Ziel treu, das Leben der Patientinnen und Patienten zu verbessern, eine Aufgabe, die mit unserem Engagement fr die Schaffung von Werten fr unsere Kunden beginnt."

Frost & Sullivan stellte in seinem Bericht fest, dass das Unternehmen mit der Umbenennung von AMRI in Curia im Jahr 2021 die Wissenschaft in den Mittelpunkt seiner Markenidentitt gestellt und sich verpflichtet hat, seinen Kunden dabei zu helfen, ber Neugierde zur Heilung ("from curiosity to cure") zu gelangen. Curia ist es gelungen, im Laufe der Zeit ein umfassendes Dienstleistungsangebot zu entwickeln, das von der Entdeckung von Arzneimitteln ber die Entwicklung bis zur Herstellung von Wirkstoffen und Arzneimitteln fr Unternehmen der Pharma– und Biobranche reicht. Die Auszeichnung wrdigt, wie Curia nach innovativen Lsungen sucht, indem es die neuesten Technologien einsetzt, um Produkte effizient von der Entdeckung ber die Entwicklung bis hin zum kommerziellen Mastab zu bringen und so die Markteinfhrung fr seine Kunden zu beschleunigen. Dieses kontinuierliche Engagement, unausgesprochene Marktbedrfnisse zu erfllen und End–to–End–Lsungen fr Kunden anzubieten, hat das Unternehmen zu einem Branchenfhrer gemacht.

"Curia hat sich seinen Ruf dadurch erworben, dass es seinen Kunden ein erstklassiges Erlebnis in Sachen Kundenorientierung und Service bietet. Das Unternehmen fhrt Umfragen bei seinen Kunden durch, um deren Gesamtzufriedenheit zu messen und sicherzustellen, dass es die hchsten Standards einhlt", so Unmesh Lal, Director, Healthcare & Life Sciences, Frost & Sullivan.

Jedes Jahr fhrt Frost & Sullivan eine strenge Bewertung durch, bei der die Auswirkungen auf das Geschft und die Kunden gemessen werden. Dabei werden die Unternehmen ermittelt, die konsequent innovativ sind, um die Bedrfnisse ihrer Kunden zu erfllen und gleichzeitig neue Herausforderungen und Chancen zu meistern. Der Gewinner wird dafr ausgezeichnet, dass er ein hervorragendes Kundenerlebnis in Bezug auf Preis, Leistung und Qualitt bietet.

ber Curia
Curia, ehemals AMRI, ist ein fhrendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen. Es bietet Pharma– und Biopharma–Kunden Produkte und Dienstleistungen von der Forschung und Entwicklung bis zur kommerziellen Herstellung. Die fast 4.000 Mitarbeiterinnen und Mitarbeiter von Curia an 29 Standorten in den USA, Europa und Asien untersttzen ihre Kunden dabei, von Kreativitt und Neugier zu Behandlungs– und Heilungsmglichkeiten zu gelangen. Erfahren Sie mehr unter CuriaGlobal.com.

ber Frost & Sullivan
Frost & Sullivan ist die Growth Pipeline Company. Wir bringen unsere Kunden in eine von Wachstum geprgte Zukunft. Unsere Growth Pipeline as a Service bietet dem CEO und dem Wachstumsteam des CEO eine kontinuierliche und strikte Plattform fr Wachstumschancen, um langfristigen Erfolg zu gewhrleisten. Unser Team kann auf ber 60 Jahre Erfahrung zurckgreifen. Dies ist hilfreich, um positive Ergebnisse zu erzielen und Unternehmen aller Arten und Gren auf 6 Kontinenten mit unseren bewhrten Best Practices zu untersttzen. Um die Zukunft Ihrer Growth Pipeline voranzutreiben, besuchen Sie Frost & Sullivan unter http://www.frost.com.

Curia–Kontaktinformationen:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com


GLOBENEWSWIRE (Distribution ID 8866428)

Curia remporte le prix Frost & Sullivan 2023 du leadership de la valeur client

ALBANY, N.Y., 29 juin 2023 (GLOBE NEWSWIRE) — Curia, une organisation de recherche, de dveloppement et de fabrication en sous–traitance de premier plan, a annonc aujourd'hui que Frost & Sullivan lui avait dcern le prix des Meilleures pratiques pour le leadership en matire de valeur client dans le secteur des CRDMO.

Nous sommes trs honors de recevoir ce prix, qui rcompense le travail acharn et le dvouement de tous nos employs pour offrir un service fiable et de qualit nos clients , a dclar Philip Macnabb, PDG de Curia. Nous restons fidles notre noble objectif d'amliorer la vie des patients, une mission qui commence par notre engagement crer de la valeur pour nos clients.

Frost & Sullivan note dans son rapport qu'AMRI, en se rebaptisant Curia en 2021, a voulu mettre la science au c"ur de son identit de marque, en insistant sur son engagement aider les clients progresser “de la curiosit la gurison”. Curia a volu au fil du temps pour offrir une gamme complte de services allant de la dcouverte de mdicaments et du dveloppement la fabrication de substances mdicamenteuses et de produits pharmaceutiques pour les entreprises pharmaceutiques et biologiques. Ce prix rcompense la manire dont Curia recherche des solutions innovantes en utilisant les technologies les plus rcentes pour faire passer efficacement les produits de la dcouverte au dveloppement et l'chelle commerciale afin d'acclrer la mise sur le march pour ses clients. Cet engagement continu rpondre aux besoins non formuls du march et fournir des solutions de bout en bout aux clients l'a positionne en tant que leader du secteur.

Curia a forg sa rputation en offrant une exprience de relation et de service client de premier ordre. L'entreprise sonde ses clients pour valuer leur satisfaction globale et s'assurer qu'elle respecte les normes les plus strictes , a dclar Unmesh Lal, directeur du dpartement Sant et sciences de la vie chez Frost & Sullivan.

Chaque anne, Frost & Sullivan procde une valuation rigoureuse, mesurant l'impact sur l'conomie et les clients, afin d'identifier les entreprises qui innovent constamment pour rpondre aux besoins de leurs clients tout en relevant de nouveaux dfis et en saisissant de nouvelles opportunits. Le gagnant est rcompens pour avoir offert une exprience client suprieure en termes de prix, de performance et de qualit.

propos de Curia
Curia, anciennement AMRI, est une organisation de recherche, dveloppement et fabrication en sous–traitance de premier plan qui fournit des produits et services allant de la R&D aux clients pharmaceutiques et biopharmaceutiques en passant par la fabrication commerciale. Bass sur 29 sites travers les tats–Unis, l'Europe et l'Asie, les prs de 4 000 employs de Curia aident les clients de l'entreprise passer de la curiosit la gurison. Pour en savoir plus, rendez–vous sur CuriaGlobal.com.

propos de Frost & Sullivan
Frost & Sullivan est la Growth Pipeline Company. Nous propulsons nos clients vers un avenir faonn par la croissance. Notre Growth Pipeline as a Service fournit au PDG et son quipe de croissance une plateforme continue et rigoureuse d'opportunits de croissance, garantissant un succs long terme. Pour obtenir des rsultats positifs, notre quipe s'appuie sur plus de 60 ans d'exprience, accompagnant des organisations de tous types et de toutes tailles sur 6 continents grce nos bonnes pratiques prouves. Pour alimenter l'avenir de votre pipeline de croissance, rendez–vous sur le site Web de Frost & Sullivan :http://www.frost.com.

Contact chez Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com


GLOBENEWSWIRE (Distribution ID 8866428)

WilsonHCG Nomeada como Líder e Estrela de Desempenho na Avaliação Global da PEAK Matrix® de 2023 de Serviços RPO do Everest Group

TAMPA, Flórida, June 29, 2023 (GLOBE NEWSWIRE) — A WilsonHCG foi nomeada Lder e Estrela de Desempenho na Avaliao anual Global da PEAK Matrix de 2023 de Servios RPO do Everest Group

A PEAK Matrix analisa a dinmica de mudana do cenrio de RPO, fornecendo uma avaliao comparativa objetiva com base em dados de mais de 45 provedores de RPO com base na sua capacidade geral em diferentes mercados de servios globais.

"Estamos honrados com a nossa nomeao como Lder e Estrela de Desempenho mais uma vez. Nosso pessoal se dedica todos os dias para ajudar na melhoria das empresas dos nossos clientes "" o que fundamental no cenrio de talentos em rpida evoluo de hoje", disse John Wilson, CEO da WilsonHCG. "Tambm estamos orgulhosos da nossa posio como Principal Concorrente na APAC, pois esta uma regio em que continuamos a expandir nos ltimos 12 meses."

Comentando sobre o status global do WilsonHCG como Lder e Estrela de Desempenho, Arkadev Basak, Parceiro do Everest Group, disse: "Juntamente com sua profunda experincia em funes altamente qualificadas de nicho de sourcing, a WilsonHCG se destaca devido sua presena e ofertas analticas globais. A aquisio da Claro e da Tracking Talent fortaleceu suas ofertas de servios e ajudou a posicionar a WilsonHCG como Lder e Estrela de Desempenho na Avaliao da PEAK Matrix de 2023 de Servios RPO do Everest Group "" Global."

O forte histrico da WilsonHCG na contratao de candidatos de colarinho branco de alta qualificao e sua duplicao no espao de sade e cincias da vida (HLS) foi elogiado pelo Everest Group, assim como sua significativa capacidade de entrega na Amrica do Norte e forte presena na EMEA.

Outros destaques da avaliao incluem:

  • Como a rede de centros de entrega global da WilsonHCG oferece suporte a vrias indstrias compradoras.
  • A vasta rede de parcerias da empresa com fornecedores de tecnologia.
  • Sua aquisio da Claro para fornecer uma oferta lder de mercado para inteligncia de mercado de talentos.

A WilsonHCG tambm foi nomeada Lder e Estrela de Desempenho na Amrica do Norte, um Concorrente Principal e Estrela de Desempenho na EMEA e Concorrente Principal na APAC.

Basak continuou: "A WilsonHCG participante principal na Amrica do Norte devido sua forte capacidade de entrega e de contratar colarinhos brancos nos nichos, principalmente de alta–tecnologia, cuidados mdicos e cincias da vida. Sua srie de investimentos orgnicos e inorgnicos para aumentar a penetrao no mercado, melhorar a capacidade tecnolgica e ofertas de consultoria ajudou no seu posicionamento como Lder e Estrela de Desempenho na Avaliao Global da PEAK Matrix de 2023 de Servios RPO do Everest Group – Amrica do Norte."

Para mais informaes sobre a PEAK Matrix , visite o site Everest Group.

Sobre a WilsonHCG

A WilsonHCG uma premiada lder global em solues totais de talentos. Como parceira estratgica ela ajuda algumas das marcas mais admiradas do mundo a desenvolver funes abrangentes de talentos. Com uma presena global em mais de 65 pases e seis continentes, a WilsonHCG fornece um conjunto completo de servios configurveis para talentos, incluindo recruitment process outsourcing (RPO), pesquisa de executivos, solues de talentos contingentes e consultoria de tecnologia.

TALENT. mais do que uma soluo; o nosso cerne.

www.wilsonhcg.com

Contato com a Mdia
Kirsty Hewitt
+44 7889901517
kirsty.hewitt@wilsonhcg.com

Foto deste comunicado disponvel em https://www.globenewswire.com/NewsRoom/AttachmentNg/4e63ef5e–761d–4037–b8b5–adce40d52acd


GLOBENEWSWIRE (Distribution ID 8866954)

WilsonHCG nommée Leader et Entreprise hors pair dans l'évaluation mondiale PEAK Matrix® 2023 des services RPO d'Everest Group

TAMPA, Floride, 29 juin 2023 (GLOBE NEWSWIRE) — WilsonHCG a t nomme Leader et Entreprise hors pair (Star Performer) une fois encore dans l'valuation mondiale PEAK Matrix 2023 des services d'externalisation des processus de recrutement (RPO) d'Everest Group.

La PEAK Matrix analyse la dynamique changeante du paysage de la RPO, fournissant une valuation comparative objective et base sur les donnes de 45 fournisseurs de RPO en fonction de leur capacit globale sur diffrents marchs mondiaux.

Nous sommes honors d'avoir t nomms Leader et Entreprise hors pair une fois encore. Nos quipes s'efforcent chaque jour d'aider nos clients amliorer leurs activits. Leur dvouement atteindre l'excellence est crucial dans le paysage des talents en volution rapide d'aujourd'hui , a dclar John Wilson, PDG de WilsonHCG. Nous sommes galement fiers de notre position de Concurrent de premier plan dans l'APAC, car c'est une rgion dans laquelle nous avons poursuivi notre expansion au cours des 12 derniers mois.

S'exprimant propos du statut mondial de WilsonHCG en tant que Leader et Entreprise hors pair, Arkadev Basak, partenaire chez Everest Group, a comment : Outre son expertise profonde en matire d'approvisionnement de talents hautement qualifis de niche, WilsonHCG se dmarque en raison de son empreinte mondiale et de ses offres analytiques. Son acquisition de Claro et Tracking Talent a renforc ses offres de services et a aid positionner WilsonHCG comme un Leader et une Entreprise hors pair dans l'valuation mondiale PEAK Matrix 2023 des services d'externalisation des processus de recrutement (RPO) d'Everest Group.

Les solides antcdents de WilsonHCG en matire de recrutement de cols blancs hautement qualifis et son engagement redoubl dans le secteur des soins de sant et des sciences de la vie ont t salus par Everest Group, ainsi que sa capacit de livraison significative en Amrique du Nord et sa forte prsence dans la rgion EMOA.

Autres faits saillants retenus dans l'valuation :

  • Comment le rseau de centres de livraison mondiaux de WilsonHCG soutient de multiples industries d'acheteurs.
  • Le vaste rseau de partenariats de la socit avec des fournisseurs de technologie.
  • Son acquisition de Claro en vue de fournir une offre de premier plan pour la veille du march des talents.

WilsonHCG a galement t nomme Leader et Entreprise hors pair en Amrique du Nord, Concurrent de premier plan et Entreprise hors pair dans la rgion EMOA, ainsi que Concurrent de premier plan dans la rgion APAC.

M. Basak a ajout : WilsonHCG es un acteur cl en Amrique du Nord grce ses fortes capacits de livraison et sa facult de recruter des cols blancs de niche en particulier dans les secteurs des hautes technologies, des soins de sant et des sciences de la vie. Sa srie d'investissements organiques et inorganiques visant accrotre sa pntration du march et amliorer ses capacits technologiques et ses offres de conseil a contribu a son positionnement en tant que Leader et Entreprise hors pair dans l'valuation PEAK Matrix 2023 Amrique du Nord des services d'externalisation des processus de recrutement (RPO) d'Everest Group.

Pour en savoir plus sur l'valuation PEAK Matrix , veuillez consulter le site Internet d'Everest Group.

propos de WilsonHCG

WilsonHCG est un leader mondial prim dans les solutions totales de talents. Oprant en tant que partenaire stratgique, la socit aide certaines de marques les plus admires au monde dvelopper des fonctions de talents compltes. Grce une prsence mondiale couvrant plus de 65 pays et six continents, WilsonHCG fournit une suite complte de services de talents configurables, notamment l'externalisation des processus de recrutement (RPO), la recherche de cadres, ainsi que des solutions de gestion de talents et de conseil en technologie.

TALENT. Plus qu'une solution, c'est notre identit.

www.wilsonhcg.com

Contact auprs des mdias
Kirsty Hewitt
+44 7889901517
kirsty.hewitt@wilsonhcg.com

Une photo accompagnant ce communiqu de presse est disponible l'adresse https://www.globenewswire.com/NewsRoom/AttachmentNg/4e63ef5e–761d–4037–b8b5–adce40d52acd


GLOBENEWSWIRE (Distribution ID 8866954)

Auszeichnung von WilsonHCG als Leader und Star Performer in der PEAK Matrix®-Bewertung 2023 für globale RPO-Dienste der Everest Group

TAMPA, Florida, June 29, 2023 (GLOBE NEWSWIRE) — WilsonHCG wurde in der jhrlichen PEAK Matrix –Bewertung der Everest Group in der Kategorie “Global Recruitment Process Outsourcing (RPO) Services” erneut als Leader und Star Performer ausgezeichnet.

Die PEAK Matrix analysiert die sich verndernde Dynamik der RPO–Landschaft und bietet eine objektive, datengesttzte vergleichende Bewertung von mehr als 45 RPO–Anbietern auf der Grundlage ihrer Gesamtfhigkeit in unterschiedlichen globalen Dienstleistungsmrkten.

"Wir fhlen uns sehr geehrt ber die erneute Auszeichnung als Leader und Star Performer. Unsere Mitarbeiterinnen und Mitarbeiter gehen jeden Tag an ihre Grenzen und darber hinaus, um die Unternehmen unserer Kunden dabei zu untersttzen, besser zu werden "" ihr Engagement fr Spitzenleistungen ist in der heutigen, sich schnell wandelnden Talentlandschaft von entscheidender Bedeutung", so John Wilson, CEO von WilsonHCG. "Wir sind auch stolz auf unsere Ernennung als "Wichtiger Mitbewerber" (Major Contender) im Asien–Pazifik–Raum, einer Region, in der wir in den letzten 12 Monaten weiter expandiert haben."

Arkadev Basak, Partner der Everest Group, kommentierte die globale Einstufung von WilsonHCG als Leader und Star Performer wie folgt: "Neben seiner umfassenden Fachkompetenz bei der Rekrutierung von hochqualifiziertem Personal fr Nischenpositionen zeichnet sich WilsonHCG durch seine globale Prsenz und sein analytisches Angebot aus. Die bernahme von Claro und Tracking Talent hat das Dienstleistungsangebot von WilsonHCG gestrkt und dazu beigetragen, dass das Unternehmen in der PEAK Matrix –Bewertung 2023 der Everest Group in der Kategorie “Recruitment Process Outsourcing (RPO) Services "" Global” als Leader und Star Performer eingestuft wurde."

Die Everest Group lobte die starke Erfolgsbilanz von WilsonHCG bei der Rekrutierung hochqualifizierter Angestellter und die Verdopplung des Engagements im Bereich Gesundheitswesen und Biowissenschaften (HLS) sowie die bedeutende Vermittlungsfhigkeit in Nordamerika und die starke Prsenz in der EMEA–Region.

Weitere Hhepunkte der Bewertung sind:

  • Untersttzung mehrerer Abnehmerbranchen durch das Netzwerk von WilsonHCG.
  • das umfangreiche Netz von Partnerschaften des Unternehmens mit Technologieanbietern.
  • die bernahme von Claro, um ein marktfhrendes Angebot fr Talentmarkt–Intelligenz zu schaffen.

WilsonHCG wurde auerdem als Leader und Star Performer in Nordamerika, als Major Contender und Star Performer in der EMEA–Region und als Major Contender in der APAC–Region ausgezeichnet.

Arkadev Basak ergnzte: "WilsonHCG ist ein wichtiger Akteur in Nordamerika aufgrund seiner starken Vermittlungsfhigkeiten und der Fhigkeit, Nischenpositionen fr Angestellte zu besetzen, insbesondere in den Bereichen Hightech, Gesundheitswesen und Biowissenschaften. Die Reihe von organischen und anorganischen Investitionen zur Erhhung der Marktdurchdringung, zur Verbesserung des technologischen und des Beratungsangebots trug dazu bei, dass das Unternehmen in der PEAK Matrix – Bewertung 2023 fr Nordamerika der Everest Group in der Kategorie "Recruitment Process Outsourcing (RPO) Services" als Leader und Star Performer eingestuft wurde".

Weitere Informationen zur PEAK Matrix finden Sie auf der Website der Everest Group.

ber WilsonHCG

WilsonHCG ist ein mehrfach ausgezeichneter, weltweit fhrender Anbieter von umfassenden Talentlsungen. Als strategischer Partner untersttzt das Unternehmen einige der angesehensten Marken der Welt beim Aufbau umfassender Talentfunktionen. Mit einer weltweiten Prsenz in mehr als 65 Lndern und auf sechs Kontinenten bietet WilsonHCG ein umfangreiches Angebot an konfigurierbaren Talent–Dienstleistungen, einschlielich Recruitment Process Outsourcing (RPO), Vermittlung von Fhrungskrften, Zeitarbeitslsungen und Beratungsdienstleistungen.

TALENT. Es ist mehr als eine Lsung, es ist das, was wir sind.

www.wilsonhcg.com

Medienkontakt
Kirsty Hewitt
+44 7889901517
kirsty.hewitt@wilsonhcg.com

Ein Foto zu dieser Mitteilung finden Sie unter https://www.globenewswire.com/NewsRoom/AttachmentNg/4e63ef5e–761d–4037–b8b5–adce40d52acd


GLOBENEWSWIRE (Distribution ID 8866954)

Mobilizing Private Capital for Adaptation: the Silent Climate Need

Investment requirements for adaptation are huge, and they are growing every day as rising emissions are increasing adaptation needs. Credit: Isaiah Esipisu/IPS - the current lead-up to COP 28 to be held later this year is an opportunity not to be missed to advance the effort to raise more private capital for adaptation

Investment requirements for adaptation are huge, and they are growing every day as rising emissions are increasing adaptation needs. Credit: Isaiah Esipisu/IPS

By Philippe Benoit and Gareth Phillips
WASHINGTON DC, Jun 29 2023 – In the climate change discourse, “mitigation” (namely, reducing greenhouse gas emissions) often dominates. This is particularly true when the discussion turns to the mobilization of the massive amounts of private capital needed to achieve our climate objections. But “adaptation” — namely, action to respond to the impacts of climate change that are already happening, as well as prepare for future impacts — also faces large funding needs.

To meet this challenge, large amounts of private capital are once again needed — and this will require climate finance innovation targeted at adaptation, specifically.

The journey from this month’s Paris climate finance summit to COP 28  hosted later this year by the United Arab Emirates – and where financing is likely to be a prominent subject — provides opportunities to raise the profile of this often overlooked need to fund adaptation.  While there is relatively little discussion of this topic, it is nonetheless a key to achieving the dual climate goals of reducing emissions while also preparing for the impacts of climate change that are now unavoidable and projected to increase.

Annual funding needs for mitigation have been estimated at around $600 billion by 2030 in emerging economies for energy alone, with private capital providing three-quarters of the required amounts. The reported needs for adaptation are relatively smaller, albeit still only partially identified. For example, annual adaptation needs for developing countries have been estimated at $160-$340 billion by 2030, including more than $50 billion for Africa. These adaptation amounts are beyond any reasonable estimate of the funding capacity of their governments, especially when added to the requirements for mitigation.

There have been various innovative financing mechanisms developed to mobilize private capital for climate but they tend to be focused on mitigation. The best known is probably the carbon markets in which investors are compensated for funding projects that reduce or otherwise avoid emissions.  Article 6 of the 2015 Paris climate agreement establishes a resource mobilization mechanism, but once again, expressly for mitigation action. Similarly, the Energy Transition Accelerator presented by U.S. Special Presidential Envoy for Climate John Kerry at COP 27, targets private capital to fund clean power sources.

When it comes to adaptation, the discussion is often focused on public sector funds. For example, the Green Climate Fund, a multi-government facility, looks to provide funding for adaptation at levels that match mitigation. Generally, adaptation projects have been seen as providing public goods and, accordingly, have looked to funding approaches reliant on public sector resources, frequently in the form of grants. This greatly limits financing options and amounts.

Yet, the investment requirements for adaptation are huge, and they are growing every day as rising emissions are increasing adaptation needs. This will require more than just public sources; private capital is needed. But in order to unlock this capital, more attention and creativity must be directed to developing new mechanisms for adaptation.

In considering private funding for adaptation, there are three distinct but interrelated major groups of actors.

  • The first are companies exposed to climate-related risks in their operations. This includes a variety of agri-businesses, electricity network enterprises, port operators, tourism industry actors and construction companies. The issue here is largely encouraging these companies to spend more on adapting their businesses to climate change.
  • A second potential source is the producers and consumers of fossil fuel products whose previous activities have fueled climate change we must adapt to. For example, just as companies have customer programs to raise finance to offset their emissions (e.g., airlines), consumers might also be motivated to support investments to address the impacts of their emissions.
  • The third and critical source is third-party private capital, including commercial banks and private equity investors. This constitutes a massive potential source of funding (the bond market totals in the trillions), and it is the focus of the discussion that follows.

The existing mitigation carbon markets provide a potentially fertile precedent for raising third-party private capital. It is important to recognize that the genesis of carbon markets was governments creating regulatory frameworks that gave value to emissions reductions — governments set targets and created mechanisms that offered both financial incentives and flexibility to meet those targets through capital spending.

This also helped lay the groundwork for the parallel non-governmental voluntary markets. Under these types of structures, investors are incentivized to pay for carbon avoidance which makes projects financially attractive — thereby providing project sponsors with access to capital for investments in activities, sectors and regions that were otherwise unbankable.

A similar approach could be taken for adaptation; namely, the creation of a regulatory or voluntary framework in which payments to projects that provide genuine adaptation benefits are recognized and valued.

Eligible adaptation actions might include climate-resilient agriculture goods and services, investments in cold storage, improved treatment and reuse of wastewater, coastal protection, conservation of biodiversity to protect nature’s ability to adapt and actions to mitigate forest fires, a topic that has received increased attention recently. Importantly, this isn’t just a musing.

The African Development Bank, where one of us is the manager of climate and environment finance, has been developing such a facility: the Adaptation Benefits Mechanism. The ABM mechanism creates a financial product for third-party investors (private capital, donors, consumers) to fund project developers in return for Certified Adaptation Benefits, which attribute a value to lowering or avoiding the negative impacts of climate change on agriculture, people’s health, biodiversity, buildings, businesses and other assets.

The ABM product is designed to be priced at a level that enables the developer to fund what would otherwise be an unbankable adaptation investment. Significantly, it provides these developers with access to new capital sources that can make more adaptation projects a reality.

Other mechanisms are being explored and deployed, such as adaptation impact bonds. Many of these programs are designed to attract third-party private capital to adaptation activities, while additional ones address other barriers and constraints to private investment.

Notwithstanding these efforts, there remains a general shortage of instruments and proposals to attract more private capital to adaptation. Overcoming this lack will require putting more intellectual and creative resources into adaptation finance, including by the world’s leading financial centers. The private sector has more to contribute to this area, but unleashing its power will require financial innovation.

With this month’s Paris climate finance summit now completed, the current lead-up to COP 28 to be held later this year is an opportunity not to be missed to advance the effort to raise more private capital for adaptation.

(First published in The Hill on June 14, 2023).

 

Philippe Benoit is research director for Global Infrastructure Analytics and Sustainability 2050 and has over 20 years of experience in international finance and sustainability, including management positions at the World Bank. He is also adjunct senior research scholar at Columbia University’s Center on Global Energy Policy.

Gareth Phillips is the manager of climate and environment finance at the African Development Bank Group.